您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

中国医药研发对照标品提供商
Non-clinical Research-used
Medicine Sample Provider

当前本网站药物产品种数共 8420 处方药 8047 非处方药 267 保健品/医疗用具 106

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国内客服电话:
国际免费电话:


QQ客服1:1793093587
QQ客服2:1586083059
QQ客服3:2786706041
QQ客服6:2992753224
QQ客服7:2394834588

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 意大利药房
产地国家: 爱尔兰
所属类别: 神经系统药物->重症肌无力
处方药:处方药
包装规格: 10毫克 100片/盒
计价单位:
  点击放大  
生产厂家英文名:
BIOMARIN INTERNATIONAL LIMITED
该药品相关信息网址1:
https://www.firdapse.com/?utm_source=google&utm_medium=cpc&utm_campaign=Brand&utm_content=Firdapse%20-%20Exact&utm_term=firdapse&gclid=Cj0KCQjw7YblBRDFARIsAKkK-dJsnSSJvPLP8_aGH3YIVLlv4YCTO3X476M3M4KEj0oCXVLu9AOpziMaAtM7EALw_wcB
原产地英文商品名:
Firdapse 10mg 100tabs/box
原产地英文药品名:
amifampridine
中文参考商品译名:
Firdapse 10毫克 100片/盒
中文参考药品译名:
氨苄西林磷酸盐
原产地国家批准上市年份:
0000/00/00
英文适应病症1:
Lambert-Eaton myasthenic syndrome (LEMS) in adults
临床试验期:
完成
中文适应病症参考翻译1:
肌无力综合征(LEMS
药品信息:

---------------------------------------------------------------
详细处方信息以本药内容附件PDF文件(20194116485739.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------
部分中文Firdapse处方资料(仅供参考)


【英文名称】
Firdapse

【适用证】

成人Lambert-Eaton肌无力综合征(LEMS)的对症治疗

【用法用量】

治疗应在有治疗疾病经验的医生的监督下开始。

剂量学

FIRDAPSE应分开给药,一天三到四次。推荐的开始 剂量为每天15毫克氨苄西林,可以每4至5天以5毫克的增量增加至a 每天最多60毫克。单剂量不应超过20毫克。

平板电脑应与食物一起服用。有关进食和禁食状态下氨苄西林的生物利用度的更多信息,请参阅第5.2节。

N-乙酰转移酶的遗传差异可以解释氨苄西林的可变全身暴露(见4.4和5.2节)。

如果停止治疗,患者可能会出现LEMS的某些症状。

肾脏或肝脏损害 对于患有肾脏或肝脏损害的患者,应谨慎使用FIRDAPSE。对于中度或重度肾功能或肝功能损害的患者,建议每天一次起始剂量为5 mg氨苄西林(半片)。对于轻度肾功能或肝功能损害的患者,建议每天起始剂量为10 mg氨苄西林(5 mg,每天两次)。患者应该比没有肾脏或肝脏损伤的患者滴定更慢,剂量每7天增加5毫克。如果发生任何不良反应,应停止向上剂量滴定(见4.4和5.2节)。

儿科人群

FIRDAPSE在0至17岁儿童中的安全性和有效性尚未确定。没有数据可用。

给药方法

仅供口服使用

【注意事项】

•对活性物质或6.1节中列出的任何赋形剂过敏

•癫痫病

•不受控制的哮喘

•与sultopride同时使用(见4.5和5.1节)

•同时使用治疗窗狭窄的药品(参见第4.5节)

•同时使用已知可能导致QTc延长的药品

•先天性QT综合征患者(见4.4节)

【Therapeutic indications】

Symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults

【Posology and method of administration】

Treatment should be initiated under supervision of a physician experienced in the treatment of the disease.

Posology

FIRDAPSE should be given in divided doses, three or four times a day. The recommended starting dose is 15 mg amifampridine a day, which can be increased in 5 mg increments every 4 to 5 days, to a maximum of 60 mg per day. No single dose should exceed 20 mg.

Tablets are to be taken with food. Please see section 5.2 for further information about bioavailability of amifampridine in the fed and fasted state.

Genetic differences in N-acetyl transferase enzymes can account for the variable systemic exposure of amifampridine (see sections 4.4 and 5.2).

If treatment is discontinued, patients may experience some of the symptoms of LEMS.

Renal or hepatic impairment

FIRDAPSE should be used with caution in patients with renal or hepatic impairment. A starting dose of 5 mg amifampridine (half tablet) once per day is recommended in patients with moderate or severe impairment of renal or hepatic function. For patients with mild impairment of renal or hepatic function, a starting dose of 10 mg amifampridine (5 mg twice a day) per day is recommended. Patients should be titrated more slowly than those without renal or hepatic impairment with doses increased in 5 mg increments every 7 days. If any adverse reaction occurs, upward dose titration should be discontinued (see sections 4.4 and 5.2).

Paediatric population

The safety and efficacy of FIRDAPSE in children aged 0 to 17 years has not been established. No data are available.

Method of administration

For oral use only

【Contraindications】

• Hypersensitivity to the active substance, or to any of the excipients listed in section 6.1

• Epilepsy

• Uncontrolled asthma

• Concomitant use with sultopride (see sections 4.5 and 5.1)

• Concomitant use with medicinal products with a narrow therapeutic window (see section 4.5)

• Concomitant use with medicinal products with a known potential to cause QTc prolongation

• In patients with congenital QT syndromes (see section 4.4)

---------------------------------------------------------------
详细处方信息以本药内容附件PDF文件(20194116485739.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------

更新日期:  2019-1-25
附件:
20194116485739.pdf    

 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国内客服电话:     国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:info.shijiebiaopin.com@gmail.com, info@shijiebiaopin.com